Skip to main content
. 2017 Jan;7(1):a027110. doi: 10.1101/cshperspect.a027110

Table 2.

Antibacterial activity of lefamulin and comparators

MIC90 (μg/mL)
Species n LMU ERY CLI DOX TGC LZD VAN DAP LEV PEN
Organisms causing predominantly SSSI and bacteremia
Staphylococcus aureus 5527 0.12 >4 >2 0.25 0.25 1 1 0.5 >4
MSSA 3157 0.12 >4 ≤0.25 0.25 0.25 2 1 0.5 1
MRSA 2370 0.25 >4 >2 1 0.25 1 1 0.5 >4
CoNS 878 0.12 >4 >2 2 0.25 1 2 0.5 >4
Enterococcus faecium 536 4 >4 >8 0.25 1 >16 2 >4
Vancomycin-nonsusceptible 304 0.25 >4 >8 0.25 1 >16 2 >4
β-Haemolytic Streptococcus spp. 763 0.03 >4 >2 8 0.06 1 0.5 0.25 1 0.06
Viridans group Streptococcus spp. 245 0.5 >4 ≤0.25 >8 0.06 1 0.5 0.5 2 0.5
n LMU ERY AZI DOX TGC LEV SXT CXM IMI PEN
Organisms causing predominantly RTI
Streptococcus pneumoniaea 1473 0.25 >4 >4 8 0.06 1 >4 8 0.5 4
Haemophilus influenzaeb 360 2 8 2 0.5 0.25 >4 2 1
Moraxella catarrhalis 253 0.25 0.25 ≤0.25 0.25 0.25 ≤0.5 2 ≤0.12 >4
Legionella pneumophilac 30 0.5 0.25 0.12 0.12
Mycoplasma pneumoniae 50 (4)d 0.006 0.0025–0.005f ≤0.0003f 0.04–0.04f
Chlamydia pneumoniae 50 (2)e 0.04 0.04–0.16f 0.08–0.16f 0.04–0.08f

Data adapted from Paukner et al. (2013c) and Sader (2012b).

MRSA, Methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; CoNS, coagulase-negative Staphylococcus spp.; AZI, azithromycin; CLI, clindamycin; CXM, cefuroxime; DAP, daptomycin; DOX, doxycycline; ERY, erythromycin; IMI, imipenem; LEV, levofloxacin; LMU, lefamulin; LZD, linezolid; PEN, penicillin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; VAN, vancomycin.

a61.3% of S. pneumoniae isolates were penicillin-susceptible.

b23.6% of H. influenzae isolates were β-lactamase-positive.

cMICs determined by agar dilution using charcoal-supplemented BCYEα medium.

dLMU was tested against n = 50 isolates, whereas comparators were tested against n = 4 isolates.

eLMU was tested against n = 50 isolates, whereas comparators were tested against n = 2 isolates.

fRange of MICs for isolates tested.